Proteostasis dysregulation and the development of Alzheimer's-like neurodegeneration and dementia in Down syndrome

唐氏综合征(DS)是一种先天性疾病，由部分或完全三联征引起 人类21号染色体。几乎所有患有DS的受试者都会发展成广泛的神经病理。 包括淀粉样蛋白-神经性斑块、突触功能障碍和神经变性，使人想起 阿尔茨海默氏症。而染色体上额外复制的淀粉样蛋白-前体蛋白(APP) 21被认为在DS的这种病理表型的发展中起主要作用， 导致这些变化的基本机制及其对 神经退行性变仍然难以捉摸。令人信服的证据支持这样一种假设 生理性细胞蛋白平衡对神经元健康至关重要，而 哺乳动物的雷帕霉素靶标(MTOR)是这一重要细胞功能的主要调节因子。 然而，虽然我们知道系统在DS中被更改，但我们不知道它是否发挥了 在DS发病机制和神经病理学发病中的功能作用。在我们的初步数据中 我们发现，与健康匹配的对照组相比，mTOR在选定的大脑中过度活跃 DS患者的区域。重要的是，我们观察到，在相同的受试者中， 与病理相关。此外，我们发现mTOR在一口井的大脑中发生了变化- 在表型的早期阶段建立了DS的小鼠模型，Ts65Dn小鼠，以及 与细胞丢失的生化证据相关联，表明mTOR， DS患者的神经病理和神经变性。考虑到科学的 根据之前发表的文献以及我们最近的发现，我们现在提出一个 新的工作假说：mTOR信号通路的改变是导致 神经病理DS表型，代表了一种新的和可行的治疗靶点 在DS受试者中。在这项提案中，我们将评估监管失调之间的时间关系 DS患者脑内mTOR的表达与神经病理发展的关系到时候我们会的 重点调查在相同的DS受试者中导致这种失调的早期事件。 接下来，为了证明其在证候发病机制中的直接作用，我们将研究 调节mTOR活性和表达水平对行为障碍和 使用DS活体模型的神经病理学。我们建议的研究结果将阐明 早期改变和继发于调控失调的蛋白平衡改变的功能后果 MTOR在DS患者神经病理表型发展中的作用重要的是 我们的发现有可能发现新的治疗机会，以延迟其发病和 /或阻止其进展。

Down syndrome (DS) is a congenital condition resulting from partial or complete triplication of human chromosome 21. Virtually all the subjects with DS develop widespread neuropathology including amyloid- neuritic plaques, synaptic dysfunction and neurodegeneration, reminiscent of Alzheimer's disease. While the extra copy of amyloid- precursor protein (APP) on chromosome 21 is thought to play a major role in the development of this type of pathologic phenotype in DS, the underlying mechanisms responsible for these changes and their contribution to neurodegeneration are still elusive. Compelling evidence supports the hypothesis that physiological cellular proteostasis is of critical importance for neuronal health and that the mammalian target of rapamycin (mTOR) is a master regulator of this vital cellular function. However, while we know that the system is altered in DS we do not know whether it plays a functional role in the pathogenesis of DS and the onset of neuropathology. In our preliminary data we found that compared with healthy matched controls mTOR is hyperactive in selected brain regions of DS patients. Importantly, we observed that in the same subjects the dysfunction directly correlates with the pathology. Moreover, we show that mTOR is altered in the brain of a well- established mouse model of DS, the Ts65Dn mice, at an early stage of the phenotype, and associates with biochemical evidence of cell loss, suggesting a link between mTOR, neuropathology and neurodegeneration in DS subjects. Taking into consideration the scientific rigor of the previously published literature together with our recent findings we now propose a novel working hypothesis: alteration of mTOR signaling pathway is responsible for the onset of the neuropathologic DS phenotype and represents a novel and viable therapeutic target against it in DS subjects. In this proposal, we will assess the temporal relationship between dysregulation of mTOR in the brain of DS patients and the development of the neuropathology. We will then focus on investigating early events responsible for this dysregulation in the same DS subjects. Next, to prove its direct role in the pathogenesis of the syndrome, we will study the effect that modulation of mTOR activity and expression levels has on behavior impairments and neuropathology using in vivo models of DS. The results of our proposed studies will elucidate early changes and the functional consequences of altered proteostasis secondary to dysregulated mTOR in the development of the neuropathologic phenotype in individuals with DS. Importantly, our findings have the potential to identify new therapeutic opportunities for delaying its onset and /or halting its progression.